High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes

Haruka Saito¹, Hayato Tanabe¹, Akihiro Kudo¹, Noritaka Machii¹, Moritake Higa², Satoshi Yamaguchi^{1,5}, Gulinu Maimaituxun¹, Kazumichi Abe³, Atsushi Takahashi³, Kenichi Tanaka⁴, Koichi Asahi⁶, Hiroaki Masuzaki⁷, Hiromasa Ohira³, Junichiro J. Kazama⁴ and Michio Shimabukuro^{1*}

¹Department of Diabetes, Endocrinology and Metabolism, ³Department of Gastroenterology and ⁴Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan; ²Department of Diabetes and Lifestyle-Related Disease Center, Tomishiro Central Hospital, Okinawa, Japan; ⁵Department of Cardiology, ⁶Division Nakagami Hospital, Okinawa, Japan; Nephrology of and Hypertension, Iwate Medical University, Iwate, Japan; ⁷Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), University of the Ryukyu, Okinawa, Japan.

*Corresponding author at: Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan; E-mail address: <u>mshimabukuro-ur@umin.ac.jp</u> (M. Shimabukuro); Tel +81-24-547-1305, Fax +81-24-547-1311

A. DKD

		D							
EID4 Inday (nor 1	Univariate	P value	Multivariate 1.285 (1.107-1.492)	P value	4		—	•	
FIB4 Index (per 1 unit)			• •		4		•		
Age (per year)	1.019 (1.007-1.032)		1.005 (0.990-1.019)		4		⊢		
Sex (male vs. female)	1.196 (0.939-1.523)		1.130 (0.816-1.565)		4				
BMI (kg/m ²)	1.001 (0.981-1.022)		1.008 (0.988-1.028)		-		•		
eGFR (mL/min/1.73 m ²)	0.989 (0.981-0.997)		0.988 (0.979-0.996)		1		- H e H		
HbA1c (%)	1.053 (0.998-1.111)		1.066 (1.004-1.133)						
Hypertension (yes vs. no)	1.473 (1.146-1.893)		1.264 (0.955-1.673)]		· ·	•	
Dyslipidemia (yes vs. no)	1.015 (0.779-1.322)		0.941 (0.713-1.241)]				
Past drinker (yes vs. no)	1.003 (0.794-1.266)		0.917 (0.680-1.239)			F			
Past smoker (yes vs. no)	1.221 (0.967-1.541)		1.244 (0.942-1.643)		1				
Sulfonylurea (yes vs. no)	1.524 (1.150-2.020)		1.411 (1.016-1.959)		1			• .	
Biguanide (yes vs. no)	1.188 (0.847-1.667)		1.088 (0.759-1.558)		1		•		
Thiazolidine (yes vs. no)	1.110 (0.621-1.981)		1.005 (0.557-1.812)		1		•	1	
αGI (yes vs. no)	1.093 (0.760-1.571)		0.844 (0.566-1.259)		1	H	- -		
Insulin (yes vs. no)			1.470 (0.936-2.311)		1		⊢	•	—
RAS inhibitor (yes vs. no)	1.616 (1.236-2.112)	<0.001	1.431 (1.060-1.932)	0.019	- <u>-</u>		H	• 1	
					0.0	0.5	1.0	1.5 2.	.0 2.5
							Hazard ra	tio	
B. eGFR < 60									
		value		value	L				
FIB4 Index (per 1 unit)	1.314 (1.142-1.511) <		. ,	0.073				·	
Age (per year)	1.055 (1.039-1.071) <	0.001 1	032 (1.012-1.052) 0	.002			-		
Sex (male vs. female)	0.809 (0.604-1.083)	0.155 0.	842 (0.558-1.269) 0	.411	7				
BMI (kg/m²)	0.999 (0.972-1.026)	0.922 1.	019 (0.995-1.044) 0	.122	1				
eGFR (mL/min/1.73 m ²)	0.953 (0.940-0.965) <	0.001 0	957 (0.944-0.970) <0	0.001	-		•		
HbA1c (%)	1.060 (0.993-1.132)	0.081 1.	111 (1.030-1.198) 0	.007	-		H		
Hypertension (yes vs. no)	1.864 (1.338-2.598) <	0.001 1.	370 (0.946-1.985) 0	.096	-		μ	•	-
Dyslipidemia (yes vs. no)	1.097 (0.784-1.536)	0.589 1.	104 (0.776-1.572) 0	.581	-	ŀ	•		
Past drinker (yes vs. no)	0.691 (0.517-0.925)	0.013 0.	867 (0.590-1.274) 0	.467	-	⊢	• · · · · ·		
Past smoker (yes vs. no)	0.851 (0.636-1.139) (0.278 1.	109 (0.771-1.594) 0	.578	-		⊢		
Sulfonylurea (yes vs. no)	1.992 (1.433-2.769) <				4		H	•	
Biguanide (yes vs. no)	1.639 (1.124-2.389)			.107	-		—	•	-
Thiazolidine (yes vs. no)	1.197 (0.588-2.435)			.896	4	ı	•		-
αGI (yes vs. no)	1.305 (0.850-2.005)				_	—	•		
Insulin (yes vs. no)	1.735 (1.052-2.860)				1			-	
RAS inhibitor (yes vs. no)	1.952 (1.429-2.666) <								
	· · · ·		, , ,		7			, ,	
					0.0	0.5	1.0	1.5 2.	.0 2.5
					0.0		Hazard ra		2.0
C. Proteinuria							112211112		
	Univariate P	value	Multivariate P	value	1				
FIB4 Index (per 1 unit)	1.195 (1.007-1.417) (0.041 1.	261 (1.051-1.513) 0	0.012	1		⊢●		
Age (per year)	0.995 (0.980-1.010)	0.518 0.	992 (0.974-1.010) 0	.391	-		•		
Sex (male vs. female)	1.644 (1.191-2.267) (0.002 1.	316 (0.865-2.001) 0	.199	-	F	•	1	
BMI (kg/m²)	1.007 (0.982-1.033)	0.561 1.	008 (0.983-1.033) 0	.543	-		•		
$eGFR (mL/min/1.73 m^2)$	1.008 (1.001-1.015)	0.026 1.	004 (0.996-1.013) 0	.329	-		•		
HbA1c (%)	1.088 (1.018-1.163)		, ,		-		⊢●⊣		
Hypertension (yes vs. no)	1.392 (1.012-1.913)		. ,	.296	-	F	• •		
Dyslipidemia (yes vs. no)	0.986 (0.708-1.373)				-		•		
Past drinker (yes vs. no)	1.286 (0.955-1.731)				-	—	•i		
Past smoker (yes vs. no)	1.739 (1.290-2.345) <				-		⊢		
Sulfonylurea (yes vs. no)	1.563 (1.108-2.204)				-	,	•		
Biguanide (yes vs. no)			091 (0.700-1.700) 0		4	-	•	-	
Thiazolidine (yes vs. no)				0.068			-	•	
αGI (yes vs. no)	1.089 (0.696-1.706)				1	•	-	-	·
Insulin (yes vs. no)	1.514 (0.892-2.570)]				
RAS inhibitor (yes vs. no)	1.567 (1.123-2.189)]				
175 minutor (yes vs. 110)	1.507 (1.125-2.109)	5.008 1.			1_		· · ·		
					0.0	0.5	1.0 1.5	2.0 2.5	5 3.0 3
					0.0	0.0	1.5	2.0 2.0	

Hazard ratio

Supplement Figure 2. Univariate and Cox proportional hazard ratios of FIB4 index (per 1 unit) for the development of (A) diabetic kidney disease (DKD: eGFR < 60 mL/min/1.73 m2 or proteinuria), (B) eGFR < 60 mL/min/1.73 m2, and (C) proteinuria in type 2 diabetic patients. Cox proportional hazard models were adjusted for age, sex, BMI, baseline HbA1c, baseline eGFR, smoking and drinking status (current or past), comorbidities (hypertension, dyslipidemia) and anti-diabetic and anti-hypertensive medications. 95% CI, 95% confidence interval.